Category: Publications
Search News
Novel insights into graft-versus-host disease
13th October 2020
Research led by Barts Cancer Institute, Queen Mary University of London, has identified a subset of immune cells involved in site-specific tissue damage in cancer patients who have developed harmful graft-versus-host disease after stem cell transplantation. The insights gained from the study may help to define new targets for more selective approaches to prevent or treat this condition in patients who have received a stem cell transplant.
Read more
Research explainer with Dr Gabriella Ficz
28th September 2020
We spoke with Dr Gabriela Ficz to find out about her recent publication in Nature Communications. The study set out to determine how embryonic stem cells can acquire features that are found in cancer cells.
Read more
Results from the Phase I STARPAC trial
24th September 2020
A treatment combination involving the addition of a form of vitamin A to the current standard treatment regimen for pancreatic cancer is safe for patients, according to an early phase clinical trial led by Professor Hemant Kocher from Barts Cancer Institute, Queen Mary University of London.
Read more
Immunotherapy for advanced bladder cancer
18th September 2020
An immunotherapy drug called ‘avelumab’ has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Professor Tom Powles.
Read more
Investigating new treatment options for mesothelioma
16th September 2020
Results from a phase I clinical trial led by Professor Peter Szlosarek were recently published in JTO Clinical and Research Reports. The trial was investigating the safety and efficacy of a new drug combination for the treatment of mesothelioma. We spoke to Professor Szlosarek to find out more about the trial, and how the drug combination may be able to help patients with mesothelioma.
Read more
Immune ‘cloaking’ in cancer cells
14th September 2020
Researchers have created a mathematical model that can determine the impact of the immune system on tumour evolution. The information gained from using this model may be able to be used to predict whether immunotherapy is likely to be effective for a patient’s cancer, helping to guide treatment decisions.
Read more